```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1655CXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JUL 20   Powerful new interactive analysis and visualization software,
                   STN AnaVist, now available
 NEWS  4  AUG 11   STN AnaVist workshops to be held in North America
 NEWS  5  AUG 30   CA/CAplus -Increased access to 19th century research documents
 NEWS  6  AUG 30   CASREACT - Enhanced with displayable reaction conditions
 NEWS  7  SEP 09   ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS  8  OCT 03   MATHDI removed from STN
 NEWS  9  OCT 04   CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                   to core patent offices
 NEWS 10  OCT 06   STN AnaVist workshops to be held in North America
 NEWS 11  OCT 13   New CAS Information Use Policies Effective October 17, 2005
 NEWS 12  OCT 17   STN(R) AnaVist(TM), Version 1.01, allows the export/download
                   of CAplus documents for use in third-party analysis and
                   visualization tools
 NEWS 13  OCT 27   Free KWIC format extended in full-text databases
 NEWS 14  OCT 27   DIOGENES content streamlined
 NEWS 15  OCT 27   EPFULL enhanced with additional content

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:14:56 ON 07 NOV 2005

=> file .biotech caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21
```

FILES 'MEDLINE, BIOTECHDS, EMBASE, BIOSIS, SCISEARCH, CANCERLIT, CAPLUS'
ENTERED AT 17:15:08 ON 07 NOV 2005

7 FILES IN THE FILE LIST

=> s oligonucleotide and tissue-specific polynucleotide
L1 1 OLIGONUCLEOTIDE AND TISSUE-SPECIFIC POLYNUCLEOTIDE

=> d all

L1 ANSWER 1 OF 1 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN 2002-02454 BIOTECHDS
TI Identifying tissue (tumor)-specific polynucleotide overexpressed in tissue of interest as compared to control tissue, for detecting cancer cells in patient, comprises DNA microarray analysis or quantitative polymerase chain reaction;
the use of tumor-specific protein, genetic subtraction, DNA microarray, and quantitative polymerase chain reaction
AU Houghton R L; Dillon D C; Molesh D A; Xu J; Zehentner B; Persing D H
PA Corixa
LO Seattle, WA, USA.
PI WO 2001075171 11 Oct 2001
AI WO 2001-US10631 2 Apr 2001
PRAI US 2000-256592 18 Dec 2000; US 2000-194241 3 Apr 2000
DT Patent
LA English
OS WPI: 2001-626449 [72]
AB A method (M1) for identifying **tissue-specific polynucleotide** (P) is claimed. (M1) involves performing a genetic subtraction to identify pool of (P) from tissue of interest (TI), performing DNA microarray analysis to identify first subset of polynucleotides (SP1) at least 2-fold overexpressed in TI, and performing quantitative polymerase chain reaction (PCR) analysis on SP1 to identify second subset of (P). Also claimed are: identifying (M2) a subset of (P) showing complementary tissue-specific expression profiles in a TI; determining (M3) the presence of a cancer cell in a patient; monitoring (M4) the progression of a cancer in a patient; a composition for detecting a cancer cell in a biological sample; and a composition containing an **oligonucleotide** primer or probe of between 15 and 100 nucleotides. The method is useful for determining the presence or absence of a cancer cell in a patient, monitoring the progression of cancer in a patient. (M1) to (M4) are useful for determining presence or absence of or monitoring progression of prostate, mamma, colon, ovary, lung, head and neck, lymphoma, leukemia, melanoma, liver, gastric etc. cancer. (127pp)
CC THERAPEUTICS, Protein Therapeutics; DIAGNOSTICS, Molecular Diagnositics; GENETIC TECHNIQUES AND APPLICATIONS, Gene Expression Techniques and Analysis; BIOINFORMATICS AND ANALYSIS, Biochips and Bioarrays; DISEASE, Cancer
CT MAMMA TUMOR-SPECIFIC PROTEIN IDENTIFICATION, GENETIC SUBTRACTION, DNA MICROARRAY, QUANTITATIVE POLYMERASE CHAIN REACTION, TISSUE-SPECIFIC GENE EXPRESSION PROFILING, DNA PROBE, DNA PRIMER, MONOCLONAL ANTIBODY, APPL. COLON, OVARY, LUNG, HEAD NECK, LYMPHOMA, LEUKEMIA, LIVER, GASTRIC CANCER THERAPY, DIAGNOSIS, MONITORING TUMOR DNA SEQUENCE PROTEIN SEQUENCE DNA ARRAY DNA AMPLIFICATION (VOL.21, NO.4)